Target: IFNAR1.
Clone: MAR1-5A3.
Specificity: Anti-IFNAR1 In Vivo Antibody - Ultra Low Endotoxin (MAR1-5A3) recognizes the extracellular domain of the IFNAR1 subunit of the mouse IFN-alpha / beta receptor.
Antigen Distribution: IFNAR1 and IFNAR2 are coexpressed on nearly all cells.
Background: The antibody when prepared specifically for In vivo functional assays blocks type I IFN receptor signaling both In vitro and In vivo without depleting IFNAR1 bearing cells. This antibody was produced by In vivo genetic immunization of IFNAR1 knockout mice with a plasmid encoding the extracellular domain of murine IFNAR1. IFNAR1 and IFNAR2 are coexpressed on nearly all cells and make up the heterodimeric receptor that binds all type I IFNs (IFN alpha and beta). Type I IFNs are a family of cytokines that have been shown to promote anti-viral, anti-microbial, anti-tumor and autoimmune responses In vivo.
Immunogen: This antibody was produced by In vivo genetic immunization of IFNAR1 knockout mice with a plasmid encoding the extracellular domain of murine IFNAR1.
Concentration: ≥ 2.0 mg/ml.
Formulation: 0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.
Purity: >98% by SDS-PAGE and HPLC.
Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 1%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
